BITR.F Stock Overview
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Biotron Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.059 |
| 52 Week High | AU$0.085 |
| 52 Week Low | AU$0.0005 |
| Beta | -0.59 |
| 1 Month Change | 17.59% |
| 3 Month Change | -15.58% |
| 1 Year Change | 219.67% |
| 3 Year Change | 17.00% |
| 5 Year Change | -8.59% |
| Change since IPO | -58.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| BITR.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -5.0% | -3.5% |
| 1Y | 219.7% | -1.7% | 20.2% |
Return vs Industry: BITR.F exceeded the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: BITR.F exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| BITR.F volatility | |
|---|---|
| BITR.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BITR.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BITR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Michelle Miller | www.biotron.com.au |
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.
Biotron Limited Fundamentals Summary
| BITR.F fundamental statistics | |
|---|---|
| Market cap | US$41.66m |
| Earnings (TTM) | -US$2.58m |
| Revenue (TTM) | US$1.06m |
38.9x
P/S Ratio-15.9x
P/E RatioIs BITR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BITR.F income statement (TTM) | |
|---|---|
| Revenue | AU$1.65m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.65m |
| Other Expenses | AU$5.67m |
| Earnings | -AU$4.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0045 |
| Gross Margin | 100.00% |
| Net Profit Margin | -244.54% |
| Debt/Equity Ratio | 0% |
How did BITR.F perform over the long term?
See historical performance and comparison